Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO, a contract research organization based in Finland, today announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients in 30 clinical sites in 5 European countries.
We are very excited to announce the acquisition of Crown […]
Crown CRO and Medical Writer Ada MacKeith part of University of Helsinki HITP group mentoring programme
In 2019 the University of Helsinki launched the HelsinkiUNI International […]
Crown CRO Oy is looking for a Medical Writing Document […]
July 6, 2021 Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced […]
Dr. Falk Pharma GmbH and Zedira GmbH have announced successful […]